Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia

Clinical Therapeutics

Volumn 25, Issue 3, 2003, Pages 904-918

  Isaacsohn, Jonathan L ^a,e   LaSalle, James ^b   Chao, George ^c   Gonasun, Leonard ^d  

^a Metab and Atherosclerosis Res Ctr   (United States)

^b Medical Arts Research Collaborative   (United States)

^c Sutter Gould Medical Foundation   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Medpace Inc ^*  (United States)

Author keywords

Atherosclerosis; Cholesterol; Coronary heart disease; Fluvastatin; NCEP; Statins

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037365168     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80113-3     Document Type: Article

References (35)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998;98:851-855.
7. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
8. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
9. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
10. Schrott HG, Bittner V, Vittinghoff E, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. JAMA. 1997;277:1281-1286.
11. Lescol®/Lescol® XL [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.
12. Appel-Dingemanse S, Sabia H, Prasad P, et al. Pharmacokinetics, safety, and tolerability of three extended-release formulations of fluvastatin in healthy subjects. Abstract presented at: European Society of Clinical Pharmacology (ESCP) Symposium; October 11-14, 2000; Basel, Switzerland.
13. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
14. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
15. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultra-centrifuge. Clin Chem. 1972;18:494-502.
16. Lipid Research Clinics Program, Manual of Laboratory Operations: Lipid and lipoprotein analysis. Washington, DC: US Department of Health, Education and Welfare; 1982. Publication no. NIH 75-628.
17. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 1978;19:65-76.
18. ALT Application Sheet (#011397600-1195). Mannheim, Germany: Boehringer Mannheim Corp; 1995.
19. AST Application Sheet (#011397800-1195). Mannheim, Germany: Boehringer Mannheim Corp; 1995.
20. Boehringer Mannheim Diagnostics CK/NAC Application Sheet. Mannheim, Germany: Boehringer Mannheim Corp; 1994.
21. CK/NAC Reagent Package Insert. Mannheim, Germany: Boehringer Mannheim Corp; 1994.
22. Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403-411.
23. Neter J, Wasserman W, Kutner M, eds. Multifactor studies. In: Applied Linear Statistical Models: Regression, Analysis of Variance, and Experimental Design. 3rd ed. Homewood, Ill: Richard D. Irwin Inc; 1974, 1985, and 1990:818-860.
24. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;82:106-107.
25. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 1992;32:630-638.
26. Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis. Clin Ther. 2001;23:177-192.
27. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32:665-672.
28. Stein EA, Davidson MH, Dobs AS, et al, for the Expanded Dose Simvastatin US Study Group. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol. 1998;82:311-316.
29. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
30. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20:58-69.
31. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.
32. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
33. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000;84:149-161.
34. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10:435-451.
35. Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.